HER2+ Breast Cancer

Kamran A. Ahmed, MD, discusses the need for multidisciplinary care in patients with HER2-positive breast cancer and leptomeningeal disease.

Mei Wei, MD, discusses the potential clinical implications of the ongoing, phase 3 CompassHER2 RD trial in HER2-positive breast cancer.

The safety and efficacy of abemaciclib will be examined in patients with hormone receptor–positive, HER2-positive, node-positive, high-risk early breast cancer who have completed standard adjuvant HER2-targeted treatment as part of the phase 3 eMonarcHER trial.

Fam-trastuzumab deruxtecan-nxki is under investigation with or without pertuzumab vs a standard-of-care regimen comprised of a taxane, trastuzumab, and pertuzumab in the frontline treatment of patients with HER2-positive metastatic breast cancer as part of the phase 3 DESTINY-Breast09 trial.

The antibody-drug conjugate vic-trastuzumab duocarmazine was found to significantly improve progression-free survival over physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP trial.

The combination of pyrotinib plus trastuzumab, docetaxel, and carboplatin (TCbH) significantly improved the total pathological complete response rate over TCbH alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.

Pertuzumab plus trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer induced a pathologic complete response similar to that achieved with docetaxel, carboplatin, trastuzumab, and pertuzumab, with less treatment-related toxicities.

Tucatinib plus trastuzumab and capecitabine maintained and even improved overall survival over placebo in pretreated patients with HER2-positive breast cancer.

Charles Powell, MD, MBA, discusses remaining questions with interstitial lung disease in HER2-positive breast cancer.

Elyse Lower, MD, discusses the importance of tucatinib in the treatment of patients with HER2-positive breast cancer.

Dr Kaklamani and colleagues take an in-depth look at data from select clinical trials in the neoadjuvant and adjuvant settings for patients with HER2-positive breast cancer.

Charles Powell, MD, MBA, discusses managing fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Bhuvaneswari Ramaswamy, MD, discusses determining treatment courses for individual patients with HER2-positive breast cancer.

Elyse Lower, MD, discusses the impact of tucatinib on the treatment of patients with HER2-positive breast cancer.

Despite a modest central nervous system overall response rate, the combination of pertuzumab and high-dose trastuzumab was found to induce clinical benefit in 68% of patients with HER2-positive metastatic breast cancer enrolled to the phase 2 PATRICIA trial.

Robert Wesolowski, MD, discusses the potential future utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Although fewer deaths were reported with neratinib in patients with HER2-positive breast cancer treated on the phase 3 ExteNET trial, the agent was not found to result in a significant improvement in overall survival after 8 years of follow-up.

Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.

Distinct gene signatures, with the exception of estrogen receptor signaling and BRCAness, are associated with pathologic complete response and invasive disease-free survival, in patients with HER2-positive breast cancer who received trastuzumab and pertuzumab alone or in combination with paclitaxel.

Charles Powell, MD, MBA, discusses the risk of interstitial lung disease in patients with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan.

Pier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.

Olwen Hahn, MD, discusses the clinical significance of the KATHERINE and FeDeriCa trials in the treatment of patients with early-stage HER2-postive breast cancer.

Olwen Hahn, MD, discusses the impact of trastuzumab emtansine on the treatment of patients with HER2-positive breast cancer.

Olwen Hahn, MD, discusses the convenience of the fixed-dose combination of trastuzumab and pertuzumab in a subcutaneous formulation in HER2-positive breast cancer.

Jane L. Meisel, MD, discusses sequencing therapies for patients with metastatic HER2-positive breast cancer.